// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























28841 Abstracts

Prognostic classification of muscle-invasive bladder cancer (MIBC) following radical cystectomy (RC) alone or with perioperative chemotherapy: Analysis of the U.S. National Cancer Database (NCDB).

Guru Sonpavde - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

PACIFIC trial: A randomized phase II study of apatorsen and abiraterone in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC) who have had PSA progression while receiving abiraterone (ABI).

Kim N. Chi - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

CB-7598

Sunitinib dose escalation after disease progression in metastatic renal cell carcinoma.

Jacques Raphael - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Sunitinib

Positive Flow Crossmatch After Negative Virtual Crossmatch -A Single Center Experience.

Q. Xu - American Transplant Congress (ATC) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Lanthanum carbonate

Eligibility criteria and endpoints in metastatic renal cell carcinoma trials.

Sarah Wong - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

A single-arm biomarker-based phase II trial of savolitinib in patients with advanced papillary renal cell cancer (PRCC).

Toni K. Choueiri - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Savolitinib

PPAR-γ Agonist Attenuates Hepatic Ischemia-Reperfusion Injury in a Mouse Model by Regulating Kupffer Cell Polarization.

I. Linares - American Transplant Congress (ATC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

Rosiglitazone maleate

Effect of decipher test on adjuvant treatment decision-making among men with high-risk pathology at radical prostatectomy: Results from a multicenter prospective PRO-IMPACT study.

John L. Gore - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

N/A

N/A

Practice Patterns in the Treatment and Monitoring of Acute Cell-Mediated Kidney Graft Rejection in Canada.

J. Leblanc - American Transplant Congress (ATC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Other

N/A

N/A

Pre-Transplant Circulating TNFR2+ Regulatory T Cells Predict Acute Rejection within the First 6 Months After Kidney Transplantation.

M.-T. Nguyen - American Transplant Congress (ATC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

N/A

N/A

Impact of modern treatment strategies on second cancer incidence for patients with early stage seminoma: A population-based study in British Columbia.

Gaurav Bahl - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Updated efficacy and tolerability of durvalumab in locally advanced or metastatic urothelial carcinoma.

Thomas Powles - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Durvalumab

Circulating tumor DNA (ctDNA) and correlations with clinical prognostic factors in patients with metastatic castration-resistant prostate cancer (mCRPC).

Daniel Khalaf - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Health-related quality of life (HRQoL) in the KEYNOTE-045 study of pembrolizumab versus investigator-choice chemotherapy for previously treated advanced urothelial cancer.

David J. Vaughn - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Pembrolizumab

The diverse genomic landscape of low−risk prostate cancer.

Matthew R. Cooperberg - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Predictors of Malignancies Across Solid Organ Transplantation.

M. Bhat - American Transplant Congress (ATC) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Muscle-invasive bladder cancer: Molecular subtypes and response to neoadjuvant chemotherapy.

Roland Seiler - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Preliminary Results of Clinical Normothermic Ex Vivo Liver Perfusion in a North American Setting.

M. Bral - American Transplant Congress (ATC) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Prescription Opioid Use Before and After Kidney Transplant: Implications for Post-Transplant Outcomes.

K. Lentine - American Transplant Congress (ATC) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Morphine

Preventing Alloimmune Rejection in Heart Transplantation by Tolerogenic Dendritic Cells Induced by GDF15 Through Up-Regulation of IDO and Inhibition of the NFκB Signalling Pathway.

Y. Zhang - American Transplant Congress (ATC) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Copyright © 2026. QuantiNova All rights reserved